CXCL12 and plasma cell myeloma: Conversely, disruption of the CXCL12/CXCR4 interaction has been shown to promote hematopoietic stem cell mobilization, promoting immunologic response of patients with non-Hodgkin lymphoma and multiple myeloma [49].